The efficacy of transfection vectors to cross the endosomal membrane into the cytosol is a central aspect in the development of nucleic acid-based therapeutics. The challenge remains the same: Delivery, Delivery, Delivery. Despite a rational and appropriate construct of triblock polymeric micelles, which could serve as an ideal platform for the co-delivery of siRNAs and hydrophobic anticancer drugs, we show here its inability to properly convey oligonucleotides to their final destination. In order to overcome biological barriers, a linear PEI comprising two orthogonal groups was synthesized, holding an appropriate balance between safety and efficacy. Micellar carriers were then formulated with this polymer to enhance endosomal siRNA release. This chemical technology also addresses the two major challenges to consider when developing novel micellar products for siRNA delivery, namely cytotoxicity of polycations and endosomal escape. Herein, we demonstrate successful release of siRNA using a polymer tailoring strategy combined with a relevant in vitro approach, considering STAT3 as a promising target in the treatment of non-small cell lung cancer (NSCLC).
The objective of this study was to qualitatively evaluate a Fab-targeting ligand preparation containing free thiol groups in the hinge region by using bevacizumab as a model. The evaluation focused on the purification of fragments through a nonaffinity-based process using a centrifugal ultrafiltration technique and mild reduction conditions for the intact production of F(ab’) fragments with specific inter-heavy-chain disulfide bonds cleavage. Under these conditions, F(ab’) fragments with a defined chemical composition were successfully obtained via proteolytic digestion followed by a controlled reduction reaction process maintaining the integrity of the binding sites. The ultrafiltration purification technique appears to be suitable for the removal of the digestive enzyme but inefficient for the removal of Fc fragments, thus requiring additional processing. A suitable analytical strategy was developed, allowing us to demonstrate the reformation of disulfide bridges between the two reduced cysteines within F(ab’) fragments.
The simulation of large molecular systems remains a daunting challenge, which justifies the exploration of novel methodologies to keep computers as an ideal companion tool for everyday laboratory work. Whole micelles, bigger than 20 nm in size, formed by the self-assembly of hundreds of copolymers containing more than 50 repeating units, have until now rarely been simulated, due to a lack of computational power. Therefore, a flexible amphiphilic triblock copolymer (mPEG45-α-PLL10-PLA25) containing a total of 80 repeating units, has been emulated and synthesized to embody compactified nanoconstructs of over 900 assembled copolymers, sized between 80 and 100 nm, for siRNA complexing purposes. In this study, the tailored triblock copolymers containing a controlled number of amino groups, were used as a support model to address the binding behavior of STAT3-siRNA, in the formation of micelleplexes. Since increasingly complex drug delivery systems require an ever more optimized physicochemical characterization, a converging description has been implemented by a combination of experimentation and computational simulations. The computational data were advantageous in allowing for the assumption of an optimal N/P ratio favoring both conformational rigidifications of STAT3-siRNA with low competitive phenomena at the binding sites of the micellar carriers. These calculations were consistent with the experimental data showing that an N/P ratio of 1.5 resulted in a sufficient amount of complexed STAT3-siRNA with an electrical potential at the slipping plane of the nanopharmaceuticals, close to the charge neutralization.
4 May 2025 in International Journal of Pharmaceutics
Peanut allergy is a significant worldwide health issue and requires innovative approaches to provide safer and more effective treatments. This study explores the potential of intradermal immunotherapy using peanut formulations combined with adjuvants. Six groups of BALB/c mice previously sensitized to peanut received intradermal treatments every other week for three months comprising of: Group 1 (G1) = Peanut extract (PE) + epinephrine (EPN); G2 = PE + EPN + topical Aldara® pretreatment; G3 = PE + EPN + topical imiquimod (IMQ) micellar gel pretreatment; G4 = PE + EPN + monophosphoryl lipid A (MPLA) + IMQ; G5 = PE + EPN + IMQ; G6 = Peanut powder + EPN + hyaluronic acid (HA). Clinical scores of peanut allergy, serological levels of peanut-specific IgE (Pe-IgE), IgG1, IgG2a, and histamine were compared before and after treatment, alongside studies on IMQ permeation and the pharmacokinetics of major peanut allergen ara h 2. Clinical scores improved significantly in all groups except G2 (trend towards improvement without statistical significance). Pe-IgE level decreased in G1, G2, and G3, while Pe-IgG1 increased in G1, G3, and G4. G3 alone showed a significant rise in Pe-IgG2a. No group was statistically superior to G1 after adjusting for differences in cumulative allergen doses received and initial IgE levels. Ex vivo experiments revealed that IMQ micellar gel in G3 enhanced skin permeation compared to Aldara®. Additionally, ara h 2 absorption was significantly reduced in naive mice treated with PE and HA. Baseline treatment of PE and EPN effectively reduced markers of peanut allergy. However, addition of TLR-agonist adjuvants or HA did not yield statistically significant improvements compared to baseline (G1).